MX2017001531A - Anticuerpos anti-trem2 y metodos de uso de los mismos. - Google Patents

Anticuerpos anti-trem2 y metodos de uso de los mismos.

Info

Publication number
MX2017001531A
MX2017001531A MX2017001531A MX2017001531A MX2017001531A MX 2017001531 A MX2017001531 A MX 2017001531A MX 2017001531 A MX2017001531 A MX 2017001531A MX 2017001531 A MX2017001531 A MX 2017001531A MX 2017001531 A MX2017001531 A MX 2017001531A
Authority
MX
Mexico
Prior art keywords
methods
trem2
disease
trem2 antibodies
dementia
Prior art date
Application number
MX2017001531A
Other languages
English (en)
Spanish (es)
Inventor
Rosenthal Arnon
Lam Helen
TASSI Ilaria
AVOGADRI-CONNORS Francesca
Schwabe Tina
Monroe Kate
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55264791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017001531(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alector Llc filed Critical Alector Llc
Publication of MX2017001531A publication Critical patent/MX2017001531A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2017001531A 2014-08-08 2015-08-08 Anticuerpos anti-trem2 y metodos de uso de los mismos. MX2017001531A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462035336P 2014-08-08 2014-08-08
US201562135122P 2015-03-18 2015-03-18
US201562135110P 2015-03-18 2015-03-18
PCT/US2015/044396 WO2016023019A2 (en) 2014-08-08 2015-08-08 Anti-trem2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2017001531A true MX2017001531A (es) 2017-05-15

Family

ID=55264791

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017001531A MX2017001531A (es) 2014-08-08 2015-08-08 Anticuerpos anti-trem2 y metodos de uso de los mismos.
MX2023000334A MX2023000334A (es) 2014-08-08 2017-02-02 Anticuerpos anti-trem2 y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000334A MX2023000334A (es) 2014-08-08 2017-02-02 Anticuerpos anti-trem2 y metodos de uso de los mismos.

Country Status (11)

Country Link
US (4) US20170240631A1 (enExample)
EP (2) EP3177322A4 (enExample)
JP (4) JP6669749B2 (enExample)
CN (1) CN107106679B (enExample)
AU (2) AU2015300787A1 (enExample)
CA (2) CA3090240A1 (enExample)
EA (1) EA201790342A1 (enExample)
IL (2) IL279606B (enExample)
MX (2) MX2017001531A (enExample)
SG (2) SG10201913611QA (enExample)
WO (1) WO2016023019A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023019A2 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2016049641A1 (en) * 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
JP7252760B2 (ja) 2016-01-22 2023-04-05 メルク・シャープ・アンド・ドーム・エルエルシー 抗凝固因子ｘｉ抗体
MX2018015757A (es) 2016-06-14 2019-05-30 Merck Sharp & Dohme Anticuerpos antifactor de la coagulacion xi.
WO2018015573A2 (en) * 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
EP3551661A1 (en) 2016-12-09 2019-10-16 Alector LLC Anti-sirp-alpha antibodies and methods of use thereof
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CN108727489B (zh) * 2017-04-19 2021-02-09 广州市第八人民医院 一种单克隆抗体zk2c2及应用
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
US11713487B2 (en) 2017-07-14 2023-08-01 The Regents Of The University Of California Methods of predicting transplant rejection risk
HRP20230675T1 (hr) 2017-08-03 2023-09-29 Alector Llc Anti-trem2 protutijela i postupci njihove uporabe
EP3681909A1 (en) * 2017-09-14 2020-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
JP7361037B2 (ja) * 2017-10-03 2023-10-13 プリベイル セラピューティクス，インコーポレーテッド ライソゾーム病の遺伝子治療
MX2020006213A (es) * 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
CN111727203B (zh) 2017-12-19 2024-04-26 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
AU2018393074B2 (en) 2017-12-19 2025-10-23 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
CN111886246B (zh) * 2017-12-29 2024-12-17 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
AU2019211326B2 (en) 2018-01-23 2025-11-27 Nextcure, Inc. B7-H4 antibodies and methods of use thereof
PE20210342A1 (es) * 2018-05-25 2021-02-23 Alector Llc Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
MA53328A (fr) 2018-07-27 2021-06-09 Alector Llc Anticorps anti-siglec-5 et leurs procédés d'utilisation
KR20210057113A (ko) 2018-09-11 2021-05-20 워싱턴 유니버시티 항-trem-2 작용제 항체
UY38407A (es) * 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) * 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
US20230132366A9 (en) 2018-11-26 2023-04-27 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
US12351629B2 (en) 2018-12-10 2025-07-08 Mor Research Applications Ltd. TREM2 antibodies and uses thereof
CA3120875A1 (en) * 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
CN109646668B (zh) * 2019-01-04 2019-10-18 厦门大学 一种多肽用于制备防治阿尔茨海默病药物的用途
SG11202108734VA (en) * 2019-02-20 2021-09-29 Denali Therapeutics Inc Anti-trem2 antibodies and methods of use thereof
WO2020194317A1 (en) * 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CN110320368A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
JP7579589B2 (ja) * 2019-07-05 2024-11-08 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Ｒａｎタンパク質関連神経学的疾患を処置するための方法
US20220372139A1 (en) * 2019-07-15 2022-11-24 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
KR20220062500A (ko) * 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CA3159055A1 (en) 2019-11-22 2021-05-27 Forest Hoyt ANDREWS Trem2 antibodies and uses thereof
CN111000978B (zh) * 2019-11-22 2023-03-10 中山大学附属第五医院 Tlt-2在制备治疗结核病药物中的应用
AU2020397888A1 (en) * 2019-12-05 2022-06-09 Alector Llc Methods of use of anti-TREM2 antibodies
CN115279790A (zh) 2020-01-13 2022-11-01 戴纳立制药公司 抗trem2抗体和其使用方法
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Cancer treatment methods
WO2021174003A2 (en) * 2020-02-26 2021-09-02 Washington University Compositions and methods for reducing resistance to or enhancing immunotherapy
US20220089726A1 (en) * 2020-08-05 2022-03-24 Vigil Neuroscience, Inc. Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonists
CN112526143B (zh) * 2020-12-03 2021-08-03 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
CN115109150B (zh) * 2021-01-31 2024-06-25 中南大学湘雅医院 新型冠状病毒单克隆抗体xy10及其应用
WO2023092146A1 (en) * 2021-11-22 2023-05-25 Vigil Neuroscience, Inc. Anti-trem2 antibody and uses thereof
AU2022413364A1 (en) 2021-12-17 2024-07-25 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
US20250059509A1 (en) * 2021-12-22 2025-02-20 Kagoshima University Method for producing macrophages, differentiation inducing agent, differentiation induction kit, method for culturing macrophages, agent for promoting macrophage propagation, kit for promoting macrophage proliferation, method for macrophage proliferation, and macrophages
CA3243690A1 (en) * 2022-02-04 2023-08-10 Vivasor Inc ANTIGEN-BINDING PROTEINS THAT BIND TO B7-H3
JP2025508740A (ja) * 2022-02-17 2025-04-10 アノキオン・ソシエテ・アノニム 抗ａｓｇｒ１ポリペプチドおよび免疫寛容のための使用
CN114395034B (zh) * 2022-03-24 2022-08-05 中国科学院微生物研究所 一种高效中和新型冠状病毒的人源抗体及其应用
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト
WO2024097798A1 (en) * 2022-11-01 2024-05-10 Vigil Neuroscience, Inc. Anti-trem2 antibody and uses thereof
WO2024160736A1 (en) 2023-01-30 2024-08-08 Isar Bioscience Gmbh Human anti-trem2 antibody for treating neurodegenerative disorders
WO2024250809A1 (zh) * 2023-06-08 2024-12-12 成都优洛生物科技有限公司 抗trem2全人源抗体或其抗原结合片段及其应用
WO2024253424A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도
WO2024262577A1 (ja) * 2023-06-21 2024-12-26 国立大学法人 鹿児島大学 ヒトマクロファージの製造方法、分化誘導剤、分化誘導キット、ヒトマクロファージの分化誘導方法、ヒトマクロファージの増殖促進剤、ヒトマクロファージの増殖促進キット、ヒトマクロファージの増殖方法及びヒトマクロファージ
WO2025015713A1 (zh) * 2023-07-19 2025-01-23 成都优洛生物科技有限公司 抗trem2人源化抗体、其抗原结合片段及其应用
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
TW202515919A (zh) 2023-09-01 2025-04-16 比利時商艾托斯比利時公司 抗ｔｒｅｍ２抗體及使用方法
WO2025072253A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12269882B1 (en) 2023-09-25 2025-04-08 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer
CN117964761B (zh) * 2023-12-21 2025-04-01 华润生物医药有限公司 抗trem2抗体及其用途

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
PT1034298E (pt) 1997-12-05 2012-02-03 Scripps Research Inst Humanização de anticorpo murino
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002519030A (ja) 1998-06-26 2002-07-02 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトシグナルペプチド含有タンパク質
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) * 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2003099331A1 (fr) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Agents renforçateurs de la résistance à l'insuline
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
EP1578367A4 (en) 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
JP2006504971A (ja) 2002-11-01 2006-02-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
BR122017024057B8 (pt) 2006-03-15 2021-05-25 Alexion Pharma Inc anticorpo que se liga à c5 e composição farmacêutica compreendendo dito anticorpo e um veículo farmaceuticamente aceitável
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
US8093360B2 (en) 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
US7673853B2 (en) 2006-10-12 2010-03-09 Cordell Eldred Ebeling Fencing section with adjustable fencing members
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2186928A1 (en) 2008-11-14 2010-05-19 Enthone, Inc. Method for the post-treatment of metal layers
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US9354228B2 (en) 2010-07-16 2016-05-31 Adimab, Llc Antibody libraries
US20130015055A1 (en) * 2011-07-11 2013-01-17 Hariharakeshava Sarpangala Hegde Dual plasma source systems and methods for reactive plasma deposition
WO2014074942A1 (en) * 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
WO2016023019A2 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016049641A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
US20170334977A1 (en) 2014-10-20 2017-11-23 The Brigham And Women's Hospital, Inc. Targeting Apolipoprotein E (APOE) in Neurologic Disease
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
AU2016334051B2 (en) 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
WO2018015573A2 (en) 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
HRP20230675T1 (hr) 2017-08-03 2023-09-29 Alector Llc Anti-trem2 protutijela i postupci njihove uporabe
EP3681909A1 (en) 2017-09-14 2020-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.

Also Published As

Publication number Publication date
JP2017523814A (ja) 2017-08-24
JP2020063268A (ja) 2020-04-23
JP7326135B2 (ja) 2023-08-15
WO2016023019A2 (en) 2016-02-11
JP2024073453A (ja) 2024-05-29
US11084875B2 (en) 2021-08-10
NZ729157A (en) 2024-08-30
JP2022081543A (ja) 2022-05-31
SG10201913611QA (en) 2020-03-30
CA3090240A1 (en) 2016-02-11
IL250115B (en) 2021-01-31
US20170240631A1 (en) 2017-08-24
CA2955086A1 (en) 2016-02-11
AU2021202840A1 (en) 2021-06-03
HK1243006A1 (zh) 2018-07-06
CN107106679A (zh) 2017-08-29
CN107106679B (zh) 2022-07-26
EP3177322A2 (en) 2017-06-14
AU2015300787A1 (en) 2017-02-02
JP6669749B2 (ja) 2020-03-18
SG11201700901SA (en) 2017-03-30
IL279606A (en) 2021-03-01
IL279606B (en) 2022-08-01
EA201790342A1 (ru) 2017-07-31
EP4066859A1 (en) 2022-10-05
US20230107639A1 (en) 2023-04-06
WO2016023019A3 (en) 2016-07-28
US20190010230A1 (en) 2019-01-10
NZ766877A (en) 2024-08-30
MX2023000334A (es) 2023-02-09
IL250115A0 (en) 2017-03-30
EP3177322A4 (en) 2018-07-18
AU2021202840B2 (en) 2024-10-31
US20190315858A1 (en) 2019-10-17
JP7730936B2 (ja) 2025-08-28

Similar Documents

Publication Publication Date Title
MX2017001531A (es) Anticuerpos anti-trem2 y metodos de uso de los mismos.
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
MX2024001803A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
GEP20227438B (en) Pd-1-binding molecules and methods of use thereof
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
BR112017023943A2 (pt) anticorpos heterodimêricos que ligam cd3 e antígenos de tumor
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
BR112013027829A2 (pt) anticorpos anti-cd40 e método de uso
MX2017010864A (es) Anticuerpos contra tau y sus usos.
BR112017022073A2 (pt) método para purificação de proteína
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
PE20190633A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
WO2014144616A3 (en) Anti-alpha v beta 5 antibodies and uses thereof